Back to search

Aristotle University Of Thessaloniki (AUTH)

Ο ρόλος των αντινεοαγγειακών παραγόντων στο διαβητικό οίδημα της ωχράς

Abstract

dc:description

The most exciting paradigm shift that we have experienced in the treatment of diabetic retinopathy has been the advent of the anti-VEGF therapy ranibizumab (Lucentis, Genentech) for diabetic macular edema (DME) The most significant effect that the RISE and RIDE data have had is that patients with center-involving DME have a good chance of substantially improving their vision vs what was possible with laser photocoagulation. (Brown et al,2013) Based on this study anti-VEGF agent is considered the first-line treatment for center-involving DME for many clinicians. However, for patients who present with localized edema that meets the ETDRS criteria, clinicians should use focal laser (Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1, Early Treatment Diabetic Retinopathy Study research group) .The visual acuity data, in the ETDRS study with laser showed that approximately 15% of patients gained 3 lines with laser, and in RISE and RIDE, approximately 40% of patients gained 3 lines with anti-VEGF. In our study we were able to show that combination treatment with laser and anti-VEGF was superior to laser monotherapy. We also showed that combination therapy reduced the number of injections during the second year of treatment and the need for laser with better outcomes in terms of BCVA and OCT thickness. Our suggestion is to start treatment with a loading dose of three monthly injections, and laser treatment on the third month. Then we suggest combination treatment with injections and laser on a prn basis. We found that there is still a role for thermal laser in DME. For noncentral DME, circinate exudates, extrafoveal disease, and other disease that meets the definition of classic clinically significant DME, laser is a reasonable first line treatment.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papavasileiou, Evangelia
  • Παπαβασιλείου, Ευαγγελία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35828

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papavasileiou, Evangelia; Παπαβασιλείου, Ευαγγελία. Ο ρόλος των αντινεοαγγειακών παραγόντων στο διαβητικό οίδημα της ωχράς. Aristotle University Of Thessaloniki (AUTH), 2015. http://hdl.handle.net/10442/hedi/35828